Latest Insider Transactions at Vista Gen Therapeutics, Inc. (VTGN)
This section provides a real-time view of insider transactions for Vista Gen Therapeutics, Inc. (VTGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VistaGen Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VistaGen Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Joshua S. Prince Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,671
+50.0%
|
$5,342
$2.96 P/Share
|
|
Jun 28
2024
|
Shawn Singh CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,854
+31.64%
|
$9,708
$2.96 P/Share
|
|
Jun 28
2024
|
Reid G. Adler CHF CORP DEVEL OFF, GEN COUNS |
BUY
Grant, award, or other acquisition
|
Direct |
4,854
+22.72%
|
$9,708
$2.96 P/Share
|
|
Jun 28
2024
|
Cynthia Lynn Anderson CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,592
+50.0%
|
$7,184
$2.96 P/Share
|
|
Dec 29
2023
|
Reid G. Adler CHF CORP DEVEL OFF, GEN COUNS |
BUY
Grant, award, or other acquisition
|
Direct |
167
+1.41%
|
$167
$1.72 P/Share
|
|
Dec 29
2023
|
Shawn Singh CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
167
+2.88%
|
$167
$1.72 P/Share
|
|
Aug 07
2023
|
Commodore Capital LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
775,756
+33.0%
|
$17,842,388
$23.15 P/Share
|
|
Jun 30
2023
|
Jerrold Duane Dotson VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
167
+4.35%
|
$167
$1.59 P/Share
|
|
Jun 30
2023
|
Reid G. Adler CHF CORP DEVEL OFF, GEN COUNS |
BUY
Grant, award, or other acquisition
|
Direct |
167
+1.43%
|
$167
$1.59 P/Share
|
|
Jun 30
2023
|
Shawn Singh CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
167
+2.96%
|
$167
$1.59 P/Share
|
|
Dec 30
2022
|
Shawn Singh CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+3.05%
|
$0
$0.09 P/Share
|
|
Dec 30
2022
|
Jerrold Duane Dotson VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+4.54%
|
$0
$0.09 P/Share
|
|
Aug 18
2022
|
Jerry B Gin |
BUY
Open market or private purchase
|
Indirect |
100,000
+50.0%
|
$0
$0.18 P/Share
|
|
Aug 18
2022
|
Jerry B Gin |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$0
$0.18 P/Share
|
|
Aug 17
2022
|
Reid G. Adler CHF CORP DEVEL OFF, GEN COUNS |
BUY
Open market or private purchase
|
Direct |
300,000
+47.27%
|
$0
$0.17 P/Share
|
|
Aug 17
2022
|
Shawn Singh CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Indirect |
600,000
+48.93%
|
$0
$0.17 P/Share
|
|
Jul 30
2022
|
Jerrold Duane Dotson VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+4.76%
|
$0
$0.75 P/Share
|
|
Jul 12
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
60,000
-0.29%
|
$0
$0.89 P/Share
|
|
Jun 30
2022
|
Mark Alan Smith CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+20.07%
|
$0
$0.75 P/Share
|
|
Jun 30
2022
|
Shawn Singh CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+3.14%
|
$0
$0.75 P/Share
|
|
May 12
2022
|
Shawn Singh CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+40.16%
|
$100,000
$1.0 P/Share
|
|
Jan 11
2022
|
Jerrold Duane Dotson VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+16.55%
|
$18,750
$1.0 P/Share
|
|
Dec 31
2021
|
Shawn Singh CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,623
+6.89%
|
$3,623
$1.66 P/Share
|
|
Dec 31
2021
|
H. Ralph Snodgrass PRES./CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,623
+5.28%
|
$3,623
$1.66 P/Share
|
|
Dec 31
2021
|
Jerrold Duane Dotson VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
3,575
+4.5%
|
$3,575
$1.66 P/Share
|
|
Dec 31
2021
|
Mark Alan Smith CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,655
+15.11%
|
$2,655
$1.66 P/Share
|
|
Sep 07
2021
|
Jerrold Duane Dotson VP, CFO |
SELL
Open market or private sale
|
Direct |
30,000
-29.19%
|
$90,000
$3.12 P/Share
|
|
Sep 02
2021
|
H. Ralph Snodgrass PRES./CHIEF SCIENTIFIC OFFICER |
BUY
Bona fide gift
|
Direct |
1,111
+1.78%
|
-
|
|
Aug 23
2021
|
H. Ralph Snodgrass PRES./CHIEF SCIENTIFIC OFFICER |
SELL
Bona fide gift
|
Indirect |
740
-2.14%
|
-
|
|
Aug 17
2021
|
H. Ralph Snodgrass PRES./CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Indirect |
3,750
+9.77%
|
$7,500
$2.73 P/Share
|
|
Jun 30
2021
|
H. Ralph Snodgrass PRES./CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,391
+3.59%
|
$3,391
$1.95 P/Share
|
|
Jun 30
2021
|
Shawn Singh CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+9.93%
|
$5,000
$1.95 P/Share
|
|
Jun 30
2021
|
Jerrold Duane Dotson VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
89,742
+20.43%
|
$0
$0.97 P/Share
|
|
Jun 30
2021
|
Jerrold Duane Dotson VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
3,044
+18.92%
|
$3,044
$1.95 P/Share
|
|
Jun 30
2021
|
Mark Alan Smith CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,260
+15.56%
|
$2,260
$1.95 P/Share
|
|
Apr 23
2021
|
Shawn Singh CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.02%
|
$5,000
$1.5 P/Share
|
|
Mar 19
2021
|
Jon S Saxe |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+30.3%
|
$2,500
$1.5 P/Share
|
|
Mar 19
2021
|
Brian J. Underdown |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$2,500
$1.5 P/Share
|
|
Dec 31
2020
|
H. Ralph Snodgrass PRES./CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+5.39%
|
$0
$0.45 P/Share
|
|
Dec 31
2020
|
Mark Alan Smith CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+33.33%
|
$0
$0.45 P/Share
|
|
Dec 31
2020
|
Jerrold Duane Dotson VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+33.33%
|
$0
$0.45 P/Share
|
|
Dec 31
2020
|
Shawn Singh CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+12.38%
|
$0
$0.45 P/Share
|